Literature DB >> 9045874

Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

M Sensi1, C Farina, C Maccalli, R Lupetti, G Nicolini, A Anichini, G Parmiani, D Berd.   

Abstract

Metastatic melanoma patients treated with an autologous DNP-modified tumor cell vaccine develop inflammatory responses in metastatic tumors characterized by infiltration of CD8+ T cells. To further define this immune response, we analyzed T cell receptor beta-chain variable (TCRBV) region repertoire in biopsy specimens and peripheral blood lymphocytes of six patients. After administration of DNP vaccine, a restricted set of TCRBV gene families was found to be expanded compared with prevaccine metastases. In several postvaccine lesions of one patient, obtained over a 2-yr period, TCRBV14+ T cells were clonally expanded and identical T cell clonotypes could be detected. Two major recurring clones were biased toward the use of TCRBJ1S5. Furthermore, T cell lines derived from two such infiltrated skin lesions and, enriched in TCRBV14+ T cells, displayed HLA-class I-restricted lysis of the autologous melanoma cells. Clonal expansion of T cells was demonstrated in the T cell-infiltrated, postvaccine metastasis of a second patient as well. These results indicate that vaccination with autologous, DNP-modified melanoma cells can expand selected clones of T cells at the tumor site and that such clones are potentially destructive to the tumor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9045874      PMCID: PMC507854          DOI: 10.1172/JCI119215

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics.

Authors:  J L Jorgensen; U Esser; B Fazekas de St Groth; P A Reay; M M Davis
Journal:  Nature       Date:  1992-01-16       Impact factor: 49.962

2.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.

Authors:  M Orita; H Iwahana; H Kanazawa; K Hayashi; T Sekiya
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

3.  Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.

Authors:  A Anichini; A Mazzocchi; G Fossati; G Parmiani
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

4.  Organization and sequences of the diversity, joining, and constant region genes of the human T-cell receptor beta chain.

Authors:  B Toyonaga; Y Yoshikai; V Vadasz; B Chin; T W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

5.  Multiple genetic mechanisms have contributed to the generation of the HLA-A2/A28 family of class I MHC molecules.

Authors:  N Holmes; P Ennis; A M Wan; D W Denney; P Parham
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

6.  Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.

Authors:  M J Browning; P Krausa; A Rowan; D C Bicknell; J G Bodmer; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

7.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens.

Authors:  P Parham; C J Barnstable; W F Bodmer
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

8.  Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.

Authors:  D Berd; G Murphy; H C Maguire; M J Mastrangelo
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

9.  An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction.

Authors:  C Genevée; A Diu; J Nierat; A Caignard; P Y Dietrich; L Ferradini; S Roman-Roman; F Triebel; T Hercend
Journal:  Eur J Immunol       Date:  1992-05       Impact factor: 5.532

10.  T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy.

Authors:  M Willhauck; T Möhler; C Scheibenbogen; M Pawlita; P Brossart; J W Schmier; U Keilholz
Journal:  Clin Cancer Res       Date:  1996-04       Impact factor: 12.531

View more
  13 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

3.  In vivo selective expansion of a tumour-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with gene-modified autologous tumour cells.

Authors:  Y Sun; P Möller; C Berking; E M Schlüpen; M Volkenandt; D Schadendorf
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

Review 4.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Improved assessment of T-cell receptor (TCR) VB repertoire in clinical specimens: combination of TCR-CDR3 spectratyping with flow cytometry-based TCR VB frequency analysis.

Authors:  H Pilch; H Höhn; K Freitag; C Neukirch; A Necker; P Haddad; B Tanner; P G Knapstein; M J Maeurer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

6.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

7.  Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.

Authors:  J A Gollob; C P Schnipper; E Orsini; E Murphy; J F Daley; S B Lazo; D A Frank; D Neuberg; J Ritz
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

Review 8.  Oligoclonal T cells in human cancer.

Authors:  E Halapi
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

9.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

Authors:  R Soiffer; T Lynch; M Mihm; K Jung; C Rhuda; J C Schmollinger; F S Hodi; L Liebster; P Lam; S Mentzer; S Singer; K K Tanabe; A B Cosimi; R Duda; A Sober; A Bhan; J Daley; D Neuberg; G Parry; J Rokovich; L Richards; J Drayer; A Berns; S Clift; L K Cohen; R C Mulligan; G Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients.

Authors:  Mark R Albertini; Michael D Macklin; Cindy L Zuleger; Michael A Newton; Stephen A Judice; Richard J Albertini
Journal:  Environ Mol Mutagen       Date:  2008-12       Impact factor: 3.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.